| Name | Title | Contact Details |
|---|
The company is focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Acessa System is cleared by the FDA and has CE mark for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Company is located in Austin, TX.
Powered by MRP wants to radically decrease healthcare cost with technology first solutions. Our commitment is to build the first digitally enabled end- to-end marketplace for Medical Aesthetic Professional. At Powered by MRP we focus on providing medical devices, resources, training, education and support to our customers to empower them to deliver top service to their clients. We are committed to a culture of collaboration where every voice is heard and understood. We believe in embracing diversity and that it brings better insight, solutions, and serves as the most intentional way to better our company. This supports our strategy, partnerships and collaboration to achieve being the most trusted Aesthetic Marketplace throughout the world.
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.
Founded in 2004 by Rob Landerholm, MD FACS and Peter Billing, MD FACS, Eviva set out to provide excellence in patient care with a focus on leading edge bariatric (weight loss) surgery. Prominently known as industry leaders in bariatrics, Eviva has also maintained steady growth in a variety of services. The objective of our founding surgeons has come to fruition and we are pleased to have acquired a growing team of physicians and specialized care providers who share the same goals. We are leaders in performing advanced laparoscopic surgical procedures as well as a variety of specialty and preventative care services. Surgical care options include bariatric surgery, orthopedic surgery, hand surgery, cosmetic surgery, general surgery and more. Our comprehensive bariatric surgery program sets a new paradigm, providing personalized care and education prior to surgery thus maximizing patient success with our complete bariatric aftercare program. Our bariatric team is comprised of various care professionals focused on the medical, nutritional, fitness and mental health of each patient.
SteadyMed Therapeutics, Inc. is a Specialty Pharmaceutical Company. SteadyMed leverages its PatchPump platform to develop its own therapeutic portfolio and partners to optimize the delivery of high volume (greater than two mL), high value, small molecule or biologic drugs. Our family of PatchPumps can be customized to deliver liquid drugs, including biologics, with a wide range of volumes and viscosities, in a consistent and controllable manner. SteadyMed aspires to redefine the parenteral therapeutics experience for patients dependent upon large doses of intravenous and subcutaneous medications: Extending the limits of parenteral therapeutics to restore freedom, joy and dignity to patients’ lives.